Daré Bioscience to merge with Pear Tree Pharma; shares up 15%

|By:, SA News Editor

Daré Bioscience ,(DARE +15%) has agreed to merge with Pear Tree Pharmaceuticals in order to secure the rights to the latter's PT-101, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy in patients with hormone receptor-positive breast cancer, including estrogen receptor-positive and progesterone receptor-positive breast cancer.

Financial terms are not disclosed.

Subscribe for full text news in your inbox